Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13177MR)

This product GTTS-WQ13177MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Acute myeloid leukemia (AML), Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13177MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3113MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA APN311
GTTS-WQ11844MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-7684
GTTS-WQ8594MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ287MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ9536MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ3834MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-054
GTTS-WQ14761MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ15878MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XMT-1536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW